This partnership follows an agreement signed in 2007 between Galderma and Zars Pharma for the promotion and distribution of Pliaglis in the US and Canada.
Humberto Antunes, CEO of Galderma, said: “This agreement is part of our strategy to offer a comprehensive range of products that improve corrective and aesthetic procedural outcomes and complement our current family of therapeutic Rx and OTC products throughout the world.”